



RESOLUTION:

A License to Heal

Adopted at the YEPP Council Meeting in Zürich on 23rd September 2017

Recognizing that:

- On the one hand, European citizens are facing rapidly rising health care costs.
- On the other hand, a third of the global population does not have access to essential medication.

Acknowledging that:

- Government funded research, in particular through universities and other knowledge institutions, effectively subsidizes pharmaceutical companies through licensing agreements.
- The development of a drug implies a social responsibility to guarantee accessibility of this drug.
- Billed drug prices are often disproportionate to the costs of research & development.

YEPP calls on:

- The European Commission to monitor legal constructions for price-inflating activities, so as to ensure the affordability of essential medicines.
- Member states to include provisions in licensing agreements of medicines developed using government funded research which increase competition.

- Member states to include provisions in licensing agreements of medicines developed using government funded research to increase the availability of essential medicines in developing countries.
- European Competition Commissioner to examine the level of competition that exists between pharmaceutical companies and take action thereafter if relationships between major industry players are found to be a leading cause of high pricing for essential medicines.